MedTrace Logo

Effect of Clopidogrel on Allergen Challenge in Asthma

NCT01955512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-05-22

No results posted yet for this study

Summary

In asthma, breathing in an allergen, such as house dust mite induces inflammation in the airways. This process appears to involve an interaction between two different sorts of blood cells, platelets and white blood cells via a receptor called the P2Y12 receptor. The purpose of this study is to determine whether the drug clopidogrel which blocks the P2Y12 receptor on platelets, reduces inflammation following breathing in house dust mite in people with mild asthma.

Conditions

Interventions

DRUG

Clopidogrel

Clopidogrel 75mg daily for 7 days

DRUG

Placebo

Matched placebo

Sponsors & Collaborators

  • University of Southampton

    lead OTHER

Principal Investigators

  • Peter H Howarth, MD · Professor of Medicine

  • Christopher L Grainge, PhD MD · Senior Lecturer in Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01955512 on ClinicalTrials.gov